Henry Thomas

Chasing sunsets on the open road.

[Henry Thomas @Henryythomass]

@RStocksworth 🔥🔥🔥

[Henry Thomas @Henryythomass]

@Ethanmedistocks 👀

[Henry Thomas @Henryythomass]

@Stockexpojen 🔥🔥

[Henry Thomas @Henryythomass]

@StocktonPe43229 International collaboration at its finest 🤌🏽

[Henry Thomas @Henryythomass]

@HumaninvestorX Amazing progress for pancreatic cancer care.

[Henry Thomas @Henryythomass]

@Ingreenvest $OSL 🚀🚀

[Henry Thomas @Henryythomass]

@OncoSil_Medical 🔥🔥

[Henry Thomas @Henryythomass]

OncoSil Medical’s cancer treating device now in Italy 🇮🇹

https://t.co/zlrCkblHLA #ASX

[Henry Thomas @Henryythomass]

$OSL

Rachel Duggan returns to OncoSil as EMEA Sales Director, bringing 15+ years of expertise in medical devices and oncology 🤌

[Editas Medicine @editasmed]

#News: Editas Medicine to participate in upcoming investor conferences. Read the press release for details: https://t.co/CkS57ILgSu #geneediting #biotechnology

[Editas Medicine @editasmed]

Excited to share that Editas’s CSO Linda Burkly was featured in Tides Global (@TidesInforma) article, “Editas partners with Genevant to advance in vivo genome editing”. Read the article at: https://t.co/fLhp1qmgy7 #geneediting #invivoediting #biotechnology

[Editas Medicine @editasmed]

Earlier today, we reported business updates and financial results for the third quarter 2024. Learn more: https://t.co/usNwkLjzlc #geneediting #biotechnology

[TMX Newsfile @newsfile_corp]

Scryb Announces Closing of Offering

Full Story: https://t.co/aJ6zgriPWU

@RelayMedical $SCYB.C $SCYB.CA $SCYRF #Biotechnology #HealthCare #CSEStocks #OTC #OTCMarkets #OTCStocks #SmallCaps #Investing

[JCOOP @ProfitGrand]

$GLYC Double PR after hours...13G for 10% (6.83m) and PR for phase 3 trial results coming up. Insiders are loading up 13G for 5m shares just last week for 8%! I said it before. Follow...The...$$$

#Biotechnology #TechNews #drug #GLYC

[Henry Thomas @Henryythomass]

Full announcement:

👉 https://t.co/m18ulivyQV

[Henry Thomas @Henryythomass]

$OSL's new $7M placement supports expanding their Macquarie Park facility, aiming to be gross margin accretive. Bell Potter's backing as Lead Manager shows strong faith in OncoSil's mission and market potential.

[Lifespan News @LifespanNews]

Researchers have developed synthetic regulatory sequences that could prevent targeted gene therapies from having effects in unwanted cell types.

Learn more: https://t.co/NWJObwzxlI
By: Josh Conway

#aging #biotechnology

[Foghorn Therapeutics @foghorntx]

Today, we provided our third quarter 2024 financial and corporate update. Learn about advances made and upcoming milestones across our pipeline of multiple therapeutics targeting novel biology in the chromatin regulatory system: https://t.co/EY8ysphC50 #biotechnology

[Immunic Therapeutics @ImmunicInc]

🔊Don’t miss the webcast on $IMUX's #FinancialResults for the third quarter ended Sep 30, 2024, including a corporate update, on 🗓️ Nov 7 at 8am ET. To participate, please register in advance at: https://t.co/SOnyv9Yihi. 💲

#Immunic #Biotechnology #FinancialReporting

[CEB Cambridge @cebcambridge]

CEB is at the heart of a brand-new programme to train the next generation of synthetic cell scientists across the UK & EU!

Find out more: https://t.co/DSgGd7uE0Z

#DrivenByCuriosity #DrivingChange

#ChemicalEngineering #Biotechnology #Cambridge